무제 문서
 
   
무제 문서
 
 
 
 
 
날짜 2010-12-02
제목 Pharma Koreana Korea Pharmaceutical News & Report
내용 Pharma Koreana May 2007 Vol.17 No.5

Contents
REGULATORY AFFAIRS
3 The first cases of reduction in prices of patent-expired original drugs raise questions
3 Pharmacoeconomic evaluation to be carried out from July
6 Pharmaceutical firms weighing administrative litigation and patent suit regarding reduction in prices of their original drugs
7 Number of drugs on the reimbursement list total 17007
9 The US core demands accepted in the Korea-US FTA negotiations
10 Damages from the Korea-US FTA estimated at ₩500 billion for pharmaceutical industry for five years
11 Multinational pharmaceutical firms expected to expand their investment in R&D
11 The number of clinical study approval records a 6.6-fold increase during the past six years
12 KFDA to make public the drug assessment and approval process
12 GMP assessment to be switched from formulation type to individual products
13 Clinical trials for eight therapeutic genes underway
14 KPA and multinational pharmaceutical firms to cooperate
15 Doctors' prescription of 881 high-priced drugs to be monitored
15 Criteria newly established for medical insurance based reimbursement for 23 anticancer agents
17 Clinical study in Japan fails to demonstrate Iressa's survival benefit
17 Nine tranquilizers to be covered by health insurance
17 Novartis Korea's Sebivo not to be covered by insurance
18 Labeling of 'tar dye addition' to become mandatory

MARKET INFORMATION
19 Foreign-invested pharmaceutical firms occupy 29.75% of the market
23 Sales gap widening between top-ranking pharmaceutical firms and low-ranking pharmaceutical firms
23 Stockholder value-based management becoming important
25 Foreign-invested pharmaceutical firms have a cash-to-sales ratio of 7.02 percent on average
26 Hanmi's Amodipin ranks first in reimbursement claim
27 Decline in sales of Bacchus and Vita500 differently influences performance of their firms
30 Pfizer Korea reduces the price of Lipitor
31 Domestic pharmaceutical firms taking up vaccines from foreign-invested pharmaceutical firms
31 Original and generic drugs to contend intensely in antihypertensive market
32 LG Life Sciences has the highest R&D costs-to-sales ratio
33 Domestic pharmaceutical firms developing 124 new drugs
34 Twelve pharmaceutical wholesalers occupy 48.6 percent of the market
35 Pharmaceutical wholesalers perform well in 2006
37 Share of pharmacies in drug distribution increasing
38 Samyang seeking M&A with a local pharmaceutical firm
38 Successive launch of anti-osteoporotic agents with long term dosing expected
39 GSK Korea to launch anti-osteoporotic and cancer-targeting drugs
39 LG Life Sciences launches world's first sustained-release growth hormone
39 Janssen Korea's OTC drugs expected to be absorbed into J&J Korea
40 Korea Johnson and Chong Kun Dang increase prices of household insecticides ahead of summer
41 Consumer sentiment improves
42 Orthopedics clinics earn most
43 Korea to open FTA talks with EU in May
44 IMF expects Korean economy to grow 4.4%
44 Foreign patients in Cheju allowed to get 4-year stay

REGULAR FEATURES
40 Sam-A makes a fresh start with its new name
40 Daewon launches Sanorex for the treatment of obesity
40 Development of new chemical drugs to benefit from various supports
41 Ilwha launches Aclaton a gastric prokinetic drug
41 Janssen Korea's Tylenol shows highest market share for two consecutive years
41 Yungjin launches HureGin Q10 containing red ginseng and Coenzyme Q10

PROFILES
46 Summary of Korean pharmaceutical manufacturers

KOREA PATENT INFORMATION
49 Patents for blockbuster products close to successive expiration
49 Sewon Cellontech obtains a patent for a therapeutic cell for bone fracture healing
50 KFDA acquires a patent on natural substances for the treatment of narcotic addiction
50 List of unexamined patents published between March 11th 2007 and April 10th 2007
58 Abstracts for patents registered between March 11th 2007 and April 10th 2007

WORLDWIDE PATENT INFORMATION
74 Worldwide patent news

REPORT
79 Import performance outlined in 2006
90 List of high-priced drugs in the second quarter of 2007

관련URL : http://www.pharmakoreana.com

 
 
 
   
무제 문서